Clinicopathological and Prognostic Value of S100A4 Expression in Gastric Cancer: A Meta-Analysis

Purposes For several years S100A4 has been implicated in tumor progression and prognosis. However, the prognostic value of S100A4 overexpression in patients with gastric cancer remains unknown. Therefore, we performed a meta-analysis to assess the relationship between S100A4 overexpression and clinical outcome of gastric cancer. Methods and Results Candidate studies were searched from PubMed, Embase, Cochrane Library, and ISI Web of Science. We included studies that evaluated the prognostic value of S100A4 expression in gastric cancer patients with regard to survival and a series of clinicopathological parameters. The pooled hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CI) were used to estimate the effects. Ten studies, all from Asia, were included in the meta-analysis. The pooled analysis showed that S100A4 overexpression was significantly associated with worse overall survival (OS) (HR=1.86, 95% CI: 1.45-2.38, p<0.00001) without heterogeneity in the data (I2=43.6%, p=0.131). Furthermore, our results showed that S100A4 overexpression was significantly correlated with some clinicopathological parameters such as tumor grade, stage, metastasis, invasion, and relapse. Conclusions The results of our meta-analysis indicate that S100A4 overexpression correlates with more adverse clinical features and a poor prognosis of gastric cancer patients in Asia, thus suggesting that S100A4 could be a useful marker to evaluate progression and prognosis of Asian gastric cancer patients. More studies from Western countries with a larger number of tumors and standardized methods are required before significant conclusions can be drawn.

Download Full-text

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

Tumor Biology ◽

10.1007/s13277-014-2128-1 ◽

2014 ◽

Vol 35 (9) ◽

pp. 8721-8731 ◽

Cited By ~ 7

Author(s):

Kong-Kong Wei ◽

Lei Jiang ◽

Yao-Yao Wei ◽

Yu-Feng Wang ◽

Xuan-Kun Qian ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Platinum Based Chemotherapy ◽

Ercc1 Expression ◽

Gastric Cancer Patients

Download Full-text

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature

World Journal of Surgical Oncology ◽

10.1186/s12957-017-1132-5 ◽

2017 ◽

Vol 15 (1) ◽

Cited By ~ 31

Author(s):

Yu-ying Lei ◽

Jin-yu Huang ◽

Qiong-rui Zhao ◽

Nan Jiang ◽

Hui-mian Xu ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Prognostic Significance ◽

Clinicopathological Parameters ◽

Her2 Expression ◽

Gastric Cancer Patients

Download Full-text

Prognostic Role of the Circulating Tumor Cells Detected by Cytological Methods in Gastric Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2016/2765464 ◽

2016 ◽

Vol 2016 ◽

pp. 1-10 ◽

Cited By ~ 3

Author(s):

Kun Zou ◽

Shuailong Yang ◽

Liang Zheng ◽

Shuyi Wang ◽

Bin Xiong

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Progression Free Survival ◽

High Status ◽

Poor Overall Survival ◽

Free Survival ◽

Gastric Cancer Patients

Objective. We performed a meta-analysis of available studies to assess the prognostic value of circulating tumor cells detected by cytological methods for patients with gastric cancer. Methods. Two authors systematically searched the studies independently with key words in PubMed, MEDLINE, EMBASE, Science Citation Index Expanded, and Cochrane Library (from inception to April 2016). The estimated hazard ratio, risk ratio, odds ratio, and their 95% confidence intervals were set as effect measures. All analyses were performed by STATA 12.0. Results. Sixteen studies were included in this meta-analysis. CTCs-high status was significantly associated with poor overall survival (HR=2.23, 95% CI: 1.86–2.66) and progression-free survival (HR=2.02, 95% CI: 1.36–2.99). CTCs-high status was also associated with depth of infiltration (OR = 2.07, 95% CI: 1.16–3.70), regional lymph nodes metastasis (OR = 1.85, 95% CI: 1.26–2.71), and distant metastasis (OR = 2.83, 95% CI: 1.77–4.52). For unresectable gastric cancer patients, CTCs-high status was significantly associated with poor overall survival, progression-free survival, and disease control rate before and during chemotherapy group. Conclusions. Our meta-analysis has evidenced the significant prognostic value of CTCs detected for both PFS and OS in gastric cancer patients. For patients treated with chemotherapy alone, we proved that CTCs detected by cytological method showed a significant prognostic value and poor response to chemotherapy.

Download Full-text

Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20171145 ◽

2018 ◽

Vol 38 (2) ◽

Cited By ~ 1

Author(s):

Jiangling Yang ◽

Sicheng Gao ◽

Jian Xu ◽

Junfeng Zhu

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Type I ◽

Breast Cancer Patients ◽

Cytokeratin 18

Cytokeratin 18 (CK18), a type I cytokeratin of the intermediate filament family, has been associated with the prognosis of cancer patients for decades. However, its exact role in predicting the clinical outcome of breast cancer remains controversial. To comprehensively investigated the prognostic value of CK18 in breast cancer, a systematically meta-analysis was conducted to explore the association between CK18 expression and overall survival. Literature collection was conducted by retrieving electronic databases Pubmed, Cochrane Library, Web of Science, EMBASE, and OVID completely (up to January 1, 2017). Nine relevant studies with 4857 cases assessing the relationship between CK18 high expression and the outcome of breast cancer patients were enrolled in our analysis. The results indicated that the high level of CK18 expression was significantly associated with overall survival of breast cancer patients via a specimen-depended manner. Reports which used serum to detect the expression of CK18 predicted a poor outcome of breast cancer (HR = 1.24, 95%CI: 1.11–1.38, P<0.0001), while studies which used tissue as specimen indicated a reverse result (HR = 0.71, 95%CI: 0.60–0.84, P<0.00001). Moreover, overexpression of CK18 was highly relevant to advanced clinicopathological parameters of breast cancer, such as progesterone receptor, human epidermal growth factor receptor-2, tumor size, tumor stage, nodal status, and tumor grade. Taken together, the present study demonstrated that CK18 might be served as a novel biomarker to predict clinicopathological features and the outcome of breast cancer.

Download Full-text

The roles of E2Fs in gastric cancer: the transcription factors E2F1/2/3/4/5 as potential therapeutic targets and E2F6/7/8 as new prognostic biomarkers in gastric cancer

10.21203/rs.3.rs-31173/v1 ◽

2020 ◽

Author(s):

Hui Li ◽

Shufen Zhao ◽

Liwei Shen ◽

Peige Wang ◽

Shihai Liu ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Expression Patterns ◽

Prognostic Significance ◽

Therapeutic Targets ◽

Tumor Grade ◽

Clinicopathological Parameters ◽

Gastric Cancer Cells ◽

Prognostic Accuracy ◽

Gastric Cancer Patients

Abstract Background E2F is a family of transcription factor proteins with multiple functions; E2F proteins are involved in cell cycle regulation, cell differentiation, the DNA damage response and cell death. Studies have shown that E2Fs have prognostic significance in many cancers, but the expression patterns and prognostic values of E2Fs in gastric cancer have not been systematically elucidated. Methods In this study, we used the ONCOMINE database and UALCAN online analysis website to compare the transcriptional levels and expression of eight E2F family members between gastric cancer and normal samples. UALCAN was also used to analyze the relationship between the expression of 8 E2F members and clinicopathological parameters. The prognostic value of the E2Fs were determined by Kaplan-Meier Plotter. A protein-protein interaction (PPI) network was constructed using the STRING database. The functions and pathways of E2F family and its neighboring 50 frequently changed genes were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software. Finally, quantitative PCR was used to verify the expression of E2Fs in gastric cancer cells. Results The expression patterns of 8 E2F members were significantly related to the clinical cancer stage and tumor grade of gastric cancer patients. High mRNA expression of E2F1/2/3/4/5 was a prognostic factor for poor OS in gastric cancer patients, while high expression of E2F6/7/8 was associated with better OS. In addition, a high mutation rate (46%) for E2Fs was observed in patients with gastric cancer. The expression levels of E2F1/2/3/5/8 in AGS and HGC27 cell lines were higher than those in normal cells, while E2F7 showed the opposite trend. Conclusions In summary, these results indicate that E2F1/2/3/4/5 can be used as potential therapeutic targets in gastric cancer, and E2F6/7/8 can be used as new prognostic markers to improve the survival rate and prognostic accuracy in gastric cancer.

Download Full-text